Geoffrey Parker Sells 36,744 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) CFO Geoffrey Parker sold 36,744 shares of Allogene Therapeutics stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $1.26, for a total transaction of $46,297.44. Following the transaction, the chief financial officer owned 1,276,796 shares in the company, valued at $1,608,762.96. This represents a 2.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Allogene Therapeutics Price Performance

Shares of ALLO stock opened at $1.20 on Friday. The company has a market capitalization of $266.26 million, a price-to-earnings ratio of -1.08 and a beta of 0.43. Allogene Therapeutics, Inc. has a one year low of $0.86 and a one year high of $3.78. The company’s fifty day moving average price is $1.20 and its 200-day moving average price is $1.26.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. Equities research analysts expect that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on ALLO shares. JPMorgan Chase & Co. restated an “underweight” rating on shares of Allogene Therapeutics in a research report on Friday, October 10th. JMP Securities reiterated a “market perform” rating on shares of Allogene Therapeutics in a report on Monday, August 4th. Wall Street Zen cut shares of Allogene Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, October 12th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Allogene Therapeutics in a research note on Friday. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $8.44.

Institutional Investors Weigh In On Allogene Therapeutics

Hedge funds have recently made changes to their positions in the company. Exchange Traded Concepts LLC increased its holdings in shares of Allogene Therapeutics by 13.5% in the 1st quarter. Exchange Traded Concepts LLC now owns 68,858 shares of the company’s stock worth $101,000 after buying an additional 8,183 shares during the last quarter. Quadrature Capital Ltd grew its position in Allogene Therapeutics by 29.6% in the second quarter. Quadrature Capital Ltd now owns 44,050 shares of the company’s stock worth $50,000 after acquiring an additional 10,059 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Allogene Therapeutics by 4.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 264,065 shares of the company’s stock worth $386,000 after acquiring an additional 10,489 shares in the last quarter. Brighton Jones LLC grew its position in Allogene Therapeutics by 81.6% in the third quarter. Brighton Jones LLC now owns 25,168 shares of the company’s stock worth $31,000 after acquiring an additional 11,311 shares in the last quarter. Finally, Hsbc Holdings PLC grew its position in Allogene Therapeutics by 17.8% in the first quarter. Hsbc Holdings PLC now owns 81,435 shares of the company’s stock worth $115,000 after acquiring an additional 12,280 shares in the last quarter. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).